Home

Edward M. MD Kaye

CIK 1522780 · CEO · last filed 2026-07-16

Edward M. MD Kaye is a CEO who has filed 130 SEC Form 4 insider transactions across 6 companies since 2011. The most recent filing shows the insider was granted $12.5K of CYTK on Jul 16, 2026. Across all open-market trades the lifetime net is −$18.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.71M

Companies

6

Total Filings

130

Lifetime Open-Market Net

-$18.32M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CYTK Director 10,434 $76.76 $800.9K -$5.51M 51 2026-07-16
STOK Director 110,874 $32.71 $3.63M -$8.05M 36 2026-06-05
Avidity Biosciences, Inc. (RNAM) Delisted Director 0 — — $0 1 2026-02-27
RNA Director 6,692 $12.34 $82.6K $0 5 2025-06-12
SRPT President & CEO 71,229 $16.78 $1.20M -$4.77M 22 2017-08-07
Sarepta Therapeutics, Inc. (AVII) Delisted SVP & Chief Medical Officer — — — $0 2 2012-04-25

Recent Filings

130 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-16 CYTK Grant (A) +151 $12.5K EDGAR
2026-06-05 STOK Grant (A) — $0 EDGAR
2026-06-01 CYTK Notice (144) −2,933 -$225.1K EDGAR
2026-06-01 CYTK Sell (S) −2,933 -$223.2K EDGAR
2026-05-27 CYTK Grant (A) +2,851 $0 EDGAR
2026-04-15 CYTK Grant (A) +191 $12.5K EDGAR
2026-03-17 STOK Exer (M) +61,750 $0 EDGAR
2026-02-27 Avidity Biosciences, Inc. (RNAM) Delisted Disp (D) −6,692 $0 EDGAR
2026-01-16 CYTK Grant (A) +197 $12.5K EDGAR
2025-12-10 STOK Sell (S) −13,430 -$433.4K EDGAR
Showing 1–10 of 130
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.